| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5382600 (Pediatric) | UPJOHN | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep, 2012
(11 years ago) | |
| US6770295 | UPJOHN | Therapeutic formulation for administering tolterodine with controlled release |
Aug, 2019
(4 years ago) | |
| US6630162 | UPJOHN | Pharmaceutical formulation and its use |
Nov, 2019
(4 years ago) | |
| US6911217 | UPJOHN | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
Nov, 2019
(4 years ago) | |
|
US6770295 (Pediatric) | UPJOHN | Therapeutic formulation for administering tolterodine with controlled release |
Feb, 2020
(4 years ago) | |
|
US6911217 (Pediatric) | UPJOHN | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
May, 2020
(3 years ago) | |
|
US6630162 (Pediatric) | UPJOHN | Pharmaceutical formulation and its use |
May, 2020
(3 years ago) | |
Detrol La is owned by Upjohn.
Detrol La contains Tolterodine Tartrate.
Detrol La has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Detrol La are:
- US5382600*PED
- US6770295
- US6630162
- US6911217
- US6770295*PED
- US6911217*PED
- US6630162*PED
Detrol La was authorised for market use on 22 December, 2000.
Detrol La is available in capsule, extended release;oral dosage forms.
Detrol La can be used as treatment of overactive bladder. treatment of urinary incontinence..
The generics of Detrol La are possible to be released after 11 May, 2020.
Drugs and Companies using TOLTERODINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2000
Treatment: Treatment of overactive bladder. treatment of urinary incontinence.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
DETROL LA family patents
